AGN to Present at American Cough Conference AGN.c ANGPF (a clinical stage Canadian pharmaceutical development company) is up 8.1% today. They announced earlier this month that they were invited to present the results from its Phase 2a Study of NP-120 for idiopathic pulmonary fibrosis and Chronic Cough, at the 9th American Cough Conference in June 2023.
Conference is the world's leading educational meeting for health care professionals involved in the research and management of patients with cough.
The most recent update from the Phase 2a Study showed Ifenprodil was much more effective at reducing cough in patients than initially reported. Good to see that AGN will be able to show these findings at such a big conference in the space.
https://ir.algernonpharmaceuticals.com/news-events/press-releases/detail/157/algernon-pharmaceuticals-invited-to-present-phase-2-ipf-and